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Abstract: Background: Medicines reuse involves dispensing quality-checked, unused medication 
returned by one patient for another, instead of disposal as waste. This is prohibited in UK commu-
nity pharmacy because storage conditions in a patient’s home could potentially impact on the qual-
ity, safety and efficacy of returned medicines. Our 2017 survey examining patients’ intentions to 
reuse medicines found many favoured medicines reuse. Our aim was to analyse the qualitative 
comments to explore people’s interpretations of what makes medicines (non-)reusable. Methods: 
Thematic analysis was used to scrutinize 210 valid qualitative responses to the survey to delineate 
the themes and super-ordinate categories. Results: Two categories were “medicines as common 
commodities” versus “medicines as powerful potions”. People’s ideas about medicines aligned 
closely with other common commodities, exchanged from manufacturers to consumers, with many 
seeing medicines as commercial goods with economic value sanctioning their reuse. Fewer of the 
comments aligned with the biomedical notion of medicines as powerful potions, regulated and with 
legal and ethical boundaries limiting their (re)use. Conclusion: People’s pro-medicines-reuse beliefs 
align with perceptions of medicines as common commodities. This helps explain why patients re-
turning their medicines to community pharmacies want these to be recycled. It could also explain 
why governments permit medicines reuse in emergencies. 
Keywords: medicines; reuse; recycle; medicines reuse; attitudes 
 
1. Introduction 
Medicines reuse is the idea that quality-checked, unused, prescribed medication re-
turned by one patient can be re-dispensed for another patient instead of disposal as waste. 
Medicines reuse is currently prohibited in the UK community pharmacy context, mainly 
because the storage conditions in a patient’s home could potentially impact on the quality, 
safety and efficacy of returned medicines kept there, outside of the formal supply chain 
[1,2]. However, disregarding medicines reuse is not a sustainable position either. Firstly, 
a third of the cost of prescribed medicinal waste relates to medicines returned to commu-
nity pharmacies for disposal [3], a problem which could arguably be addressed with the 
implementation of a safe medicines reuse programme. Secondly, unpredictable events 
such as pandemics [4] and drug shortages [5] continue to force the UK government to 
temporarily relax its rules on medicines reuse in any case, a situation which could be made 
safer with better investment and research into secure medicines reuse practices. 
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Internationally, doctors, academics and officials have been debating medicines reuse 
for many decades. Canadian doctors, for example, have called for the recycling of expen-
sive cancer drugs for disadvantaged patients [6], and in the UK in 2012, even the then 
director of the NHS Sustainable Development Unit argued for research-informed debate 
on medicines reuse [7]. Indian academics have called for medicines reuse to be explored 
[8], and researchers from Italy have examined the pros and cons of donating returned 
medicines to organizations in Europe, Africa and Latin America against WHO’s formal 
advice to withhold such donations [9]. However, it is also worth noting that research 
shows that underground medication exchange activities are already taking place among 
patients, for example with diabetes medication [10], which negates these “intellectual” 
arguments about medicines reuse. Another example is a study in Iran, reporting the fre-
quent self-reuse of antibiotics by people who keep their medicines in places such as their 
fridge in case they are needed at a later time [11]. This type of “illicit” medicines reuse 
practice even extends to the scavenging and the onward recycling of medicines from 
waste disposal sites in some developing countries [12]. Thus, the concept of medicines 
reuse does not just remain relevant conceptually, it can also be considered an urgent pub-
lic health issue because informally it already takes place, further warranting research. 
The uncertainties about the quality, safety and efficacy of returned medicines relate 
to the chemical and physical properties of medicines, which can be affected by fluctua-
tions in the environment in which medicines are kept in a patient’s home, including 
changes in temperature, light, humidity, cleanliness and motion/agitation. It is conse-
quently possible for the active ingredient of the medication to degrade, or the formulation 
to break down so that ultimately less of the medicine is available to treat the disease. Yet, 
some countries around the world have already instigated medicines reuse schemes but 
without sophisticated ways of checking for the potential impact of the storage conditions 
on the stability of the medication. For instance, in Athens, Greece, the GivMed programme 
allows people access to leftover medicines [13]. Similarly, in many states of the United 
States (US), medicines donation and reuse programmes exist to support those unable to 
afford medicines [14]. The practice also appears to have been taking place in the Kingdom 
of Brunei since 2006 [15]. In these schemes, donated medicines are checked by licensed 
pharmacists against specific criteria to allow their re-dispensing. However, these checks 
are largely visual and although they might prevent the re-entry of obviously damaged 
medicines into the system, they cannot realistically safeguard against physically or chem-
ically degraded content being inadvertently accepted for reuse. This is because visual 
checks are a mere proxy marker of quality—they do not reveal the storage history of re-
turned medicines nor the impact of that history on the contents within. Thus, for example, 
a product that requires cold storage could be brought back for reuse, having been kept at 
room temperature, without necessarily showing physical signs of damage. This is against 
a backdrop of research that shows, for example 58.3% of patients store their thermolabile 
medicines outside of the correct temperature recommendations [16]. 
In the UK, the COVID-19 pandemic caused the government to permit care homes 
and hospices to draw up standard operating procedures to enable medicines reuse if im-
pacted by shortages [17]. However, here again, the quality checks relied on the visual in-
spection of any potential medicines rather than any in-depth safeguards, very similar to 
the protocol for the evaluation and redistribution of donated medicines used in a pilot 
medication recycling project in Singapore [18]. This type of practice exposes potential con-
tradictions in the very conceptualization of returned medicines by those in positions of 
power—on the one hand, these are deemed potentially unsafe and must not be reused 
because their content might have degraded, and on the other, they are deemed safe on 
passing visual and expiry checks (as proxies for the potency of the active ingredient and 
formulated medicine inside). 
When the public are asked about medicines reuse in formal studies, conflicting ideas 
about medicines are again highlighted. For example, people interviewed in an Australian 
study about medication waste questioned whether expired medicines are really totally 
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worthless or could be somehow reused, while also referring to these as “cast-offs” [19]. In 
the UK too, the people we interviewed in 2016 juxtaposed the potential economic and 
environmental benefits of medicines reuse with stability and safety worries [20]. The latter 
was also a predominant feature of interviews conducted in the Netherlands in 2014/15, 
where the potential to prevent medication waste was set against a guarantee of product 
quality for any re-dispensed medication [21]. In 2017, we developed and validated a the-
ory of planned behaviour-based medicines reuse questionnaire and used this to survey 
over a thousand people with at least one chronic health condition in the UK [22]. We 
showed that people could be encouraged to embrace medicines reuse via practical 
measures that illustrate the safety and quality assurance of reissued medicines, educa-
tional interventions that bolster beliefs about the pro-environmental benefits, and norm-
based interventions, encouraging doctors and pharmacists to endorse the practice. Based 
on ours and others’ work, it is certainly clear then that ordinary people, when questioned, 
also recognize the need for medicines to be quality-assured if they are to be reused. What 
remains unresolved, however, is whether people understand the nuanced way in which 
the quality of medication might degrade and, in turn, need to be assured, i.e., whether 
they recognize medicines as complicated entities worthy of a greater level of scrutiny than 
visual inspections alone if their safety and quality is to be checked. This is important for 
the success of wide-scale medicines reuse programmes which would rely on patient up-
take. The topic is also important to help explain how medicines on the one hand are 
deemed potentially unsafe and not reusable by policy makers (because their content might 
have degraded), yet on the other, deemed safe on passing visual and expiry checks in 
emergencies and other cases. The core interest of this paper, therefore, is to study how 
people conceptualize medicines and the properties that make them reusable or not. 
The specific aim was to thematically analyse the qualitative responses in our 2017 
survey on medicines reuse [22] to explore people’s interpretations of the properties of 
medicines that made them (non-)reusable in order to explore and study the presence of 
contradictions or conflicting ideas which both make medicines “reusable” and do not, in 
our participants’ view. 
2. Materials and Methods 
The primary data for this study came from our 2017 survey that employed the med-
icines reuse questionnaire and was completed by 1003 people who had at least one chronic 
health condition [22]. It is important to highlight that a quantitative analysis of the survey 
responses has already been published elsewhere [22]. This survey itself was developed as 
part of the Ph.D. of one of the co-authors (H.A.) and the publication referenced above 
contains full details of the questionnaire items, their development and validation, the dis-
tribution of the survey as well as the demographics of the participants [22]. The survey 
had a representative number of participants from across the UK in terms of gender, eth-
nicity, geographical location and educational level and readers are again referred to the 
existing publication for the participant details [22]. 
Within the responses, there were 210 valid qualitative comments to analyse in re-
sponse to the question “If you have any comments, or ideas regarding the concept of med-
ication reuse, please share them here”. These comments were extracted into an Excel 
spreadsheet for the analysis. 
Thematic analysis was employed for the analysis [23]. This approach was used be-
cause it provided a way of organising the qualitative data in the form of themes: recurrent 
topics, ideas or statements identified across the corpus of data. P.D. reviewed all the qual-
itative comments to confirm that names or other information that might identify the par-
ticipants had been removed. The comments were analysed manually by M.C. in consulta-
tion with P.D., according to the six phases described by Braun and Clarke [23]. The process 
involved familiarisation with the data, coding, searching for themes, reviewing themes, 
defining and naming themes, and writing up, as follows. 
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After familiarisation with the data, M.C. coded each comment and assigned initial 
“code names”. These codes first reflected what made medicines “reusable” and what did 
not. Consider the following three examples: 
Example 1. “It is worth thinking about to save the NHS money...” 
Example 2. “If they are sealed and none taken out the pack this would help the NHS save money.” 
Example 3. “Providing the products were in date, quality checked, safety checked, and original 
packing I would have no objections as it should save the NHS a huge amount of money.” 
Example 1 was initially assigned the code “NHS saving” based on the essence of what 
was being communicated. Example 2 was also coded “NHS saving” but also with the 
codes “appearance” and ”packaging”. Finally, example 3 was given numerous codes, 
“quality”, “expiry”, “safety”, “packaging”, and “NHS savings”. This process was com-
pleted for the entire list of 210 comments. This constituted what is known as first-order 
coding, the lowest level of coding where the aim is simply to organize and categorize the 
data by capturing chunks of ideas and giving them labels in a purely descriptive way with 
minimal interpretation. 
Once all the initial codes had been generated, it was possible to group the codes ac-
cording to recurrent topics or ideas by seeing the patterns in ideas from one quote to an-
other. This second-level coding aimed to go beyond the simple description of the data to 
instead interpret the meaning of the words. Here, labels were devised which captured the 
meaning of larger segments of the data, thus reducing the number of codes by sorting 
ideas into broader and more encompassing categories. Thus, for example, the initial codes 
of “packaging”, “expiry”, and “appearance” were grouped according to the theme of 
“physical appearance”. Here, the interpretive element is the description given to the cat-
egory, that “the external features and overall physical appearance of a commodity are 
adequate to indicate what is held within. Therefore, intact sealed packaging of medicines 
suggests an authentic product of good quality inside”. 
The final stage of coding involved drawing out the overarching themes within the 
data. The aim of this third-order coding was to identify superordinate constructs that were 
more global so that larger-scale patterns could be identified. This was completed by con-
tinuing to check and compare the ideas, checking other relevant literature in the field and 
even standing back from the data so that more general concepts and patterns could be 
drawn out. Thus, for example, the theme of “physical appearance”, identified above, was 
placed within the superordinate category of “medicines as common commodities” which 
encapsulates commonly held ideas about what makes medicines the same as any other 
commodity and therefore suitable for reuse. It was at this stage that the two superordinate 
categories, described more fully in the Results section below, were formed. 
3. Results 
Two super-ordinate categories encapsulated people’s ideas about what made medi-
cines “reusable” or not, each with four distinct themes. The categories and themes and 
their explanations are provided in Table 1 and further described in the text below. 
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Table 1. The concepts developed after the analysis of medicines reuse beliefs, including the two main categories “medi-
cines as common commodities” and “medicines as powerful potions” with their themes and explanations. 
Medicines as Common Commodities Medicines as Powerful Potions 
This category encapsulates commonly held ideas about what 
makes medicines the same as any other commodity and therefore 
suitable for reuse. 
This category describes what confers medicines their potency 
and special status distinct from ordinary commodities, thus cau-
tioning against reuse. 
Physical appearance The drug development process 
The external features and overall physical appearance of a com-
modity are adequate to indicate what is held within. Therefore, in-
tact sealed packaging of medicines suggests an authentic product 
of good quality inside. 
Drug discovery and development processes are time consum-
ing, expensive and intricate. Numerous stages ensure stable and 
effective final formulations, making medicines complex com-
pared to other commodities. 
Social life of medicines Specially regulated products 
Medicines have metaphorical life stages, with a medicine’s death 
(when consumed) resulting in its afterlife (internal effects) to re-
store, improve or maintain health. Failure to reuse unused medica-
tion therefore makes its existence meaningless. 
Medicines are strictly regulated by authorities to illustrate qual-
ity, safety and efficacy before and after authorization. This in-
cludes giving expiry dates and storage conditions to maintain 
the shelf life. 
Social and economic benefit Unique to an individual’s health 
Here, medicines are standardized commercial goods with eco-
nomic value, exchanged between manufacturers and consumers to 
meet their needs. Reusing medicines thus brings benefit by reduc-
ing medicines spending and waste. 
Medicines are prescribed for specific individuals with the 
unique therapeutic effects dependent on the individual’s cir-
cumstances. Medicines must not be reshared as their outcome in 
others cannot be guaranteed. 
False analogy Handling to meet legal and practice guidelines 
This fallacy assumes that if two things are alike in one aspect, then 
they will be similar in another aspect too. Thus, if devices and ap-
pliances used to diagnose and treat health conditions can be re-
used, then so can medicines. 
The sale or exchange of medicines (over the counter or via pre-
scription) must adhere to legal protocols and accuracy and clini-
cal checks. As powerful substances, their casual handling could 
cause harm to patients. 
The majority of people’s views related to ideas and concepts that defined medicines 
as common commodities, sanctioning their reuse (Figure 1). 
 
Figure 1. The number of times each theme was identified in the qualitative comments from the 210 survey participants. 
Note. Some comments were categorized according to two or more themes. 
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3.1. Medicines as Common Commodities 
The four themes within this category relate to how people see medicines as similar 
to any common commodity. Most of the patient comments fell within these themes. 
3.1.1. Physical Appearance 
This theme encapsulates the idea that the external appearance of medicines, the pack-
aging, neatness and overall visual state, are a strong indicator of the quality of what is 
held within. These superficial features thus, apparently, reflect the quality and function 
of the drug. Individuals made positive comments about the idea of reuse by relating to 
different physical features of the packaging as an indicator of quality. For example, the 
seal on the packaging was mentioned numerous times with the idea being that a sealed 
product would be suitable for reuse. The logic is that a blister pack that is presented with 
a seal and is completely labelled with no damage such as creases or torn edges would 
suggest the medicine inside is unchanged, safe, and appropriate to be reused. For exam-
ple: 
“When will the reuse of medication become legal? As long as it’s sealed, I would be 
happy.” (Participant 91). 
“As long as medication is in sealed blister packs showing expiry date then it has to be a 
good thing.” (Participant 23). 
“No reason at all not to re-use medication that is sealed and labelled.” (Participant 185). 
3.1.2. Social Life of Medicines 
This theme originates from studies within the field of medical anthropology, which 
position medicines as commodities with life stages, playing various roles in each stage to 
restore, improve and maintain health. The stage of medication death reflects the consump-
tion and administration of medicines, with the afterlife where the desirable effects of med-
icines are produced within the human body. According to this concept, wasting and de-
stroying medicines that are unused and unexpired, and not reusing them, results in a 
meaningless existence for the medicines themselves because they are not used to their 
complete potential. Thus, many regretted that medicines were being “wasted” and espe-
cially as it looked like “nothing was wrong” with them, where the outer appearance re-
mained intact. For example: 
“Please do it. I have had to return medication in the past just for it to be thrown away. 
It is wrong and wasteful when there is nothing wrong with it.” (Participant 112). 
“I think it is a brilliant idea. I have returned medication to the pharmacy in the past and 
thought it wasteful to destroy.” (Participant 135). 
“Having had to return medication from 2 people who died and had much surplus, it has 
always seemed to be to be such a waste.” (Participant 177). 
3.1.3. Social and Economic Benefit 
Here, people see medicines as commercial goods. The exchange of medicines allows 
people to meet their health requirements, and businesses to meet their targets and profits. 
Within this theme, reusing medicines, i.e., the re-exchange of pharmaceuticals between 
pharmacies and patients, benefits the public and the NHS by reducing healthcare costs 
and medicinal waste. This was the most commonly occurring theme. Many individuals 
positively encouraged the reuse of medicines because, they postulated, this would help 
the economy, i.e., reduce NHS and patient expenses, reduce waste produced from the 
destruction of unused and unwanted medicines, and allow the environment to be kept 
cleaner by minimizing landfill waste. In general, patients expressed a clear link between 
reusing medicines and a reduction in healthcare costs. This suggests medicines are given 
an economic value, similar to other common commodities. For example: 
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“I am entirely in favour of reusing medication. Far too much is wasted at great expense 
to the NHS and thus the taxpayer.” (Participant 10). 
“Blisters go to landfill and cannot be recycled.” (Participant 40). 
“I believe that unused, unopened pills should be reused, instead of being destroyed. Even 
given free to places where medications are too expensive for people who are living in 
poverty.” (Participant 191). 
3.1.4. False Analogy 
This theme draws upon people’s current knowledge of the types of products that are 
currently reused within healthcare. The fallacy assumes that if two things are alike in one 
or more aspects, then they will also be alike in another aspect. Thus, because all pharma-
ceutical goods including medicines, appliances and devices are used with the intention to 
diagnose, treat or prevent diseases, reusing one product should mean that all others are 
also suitable for reuse. For example, if dressings and medical devices that have not been 
opened or tampered with can be reused, then so can medicines, including solid and liquid 
dosage forms. For example: 
“(reuse) Applies to other things within NHS e.g., dressings, stoma products.” (Partic-
ipant 21). 
“As long as medication/dressing etc. has not been tampered with, use and not waste 
them.” (Participant 149). 
3.2. Medicines as Powerful Potions 
The four themes within this category relate to the special features of medication that 
set them apart from ordinary commodities. Less than a quarter of the comments reflected 
these themes. 
3.2.1. The Drug Development Process 
Drug discovery and development processes are time consuming, expensive and com-
plex. There are many stages involved in producing highly stable and effective formula-
tions of drugs, including pharmacological and pharmacokinetic testing, along with their 
manufacturing. Thus, the development and maintenance of medicines being complex, sets 
them apart from everyday commodities. A limited number of comments reflected this 
theme. Participants mentioned the need for scientific data, evidence, and published trials 
to evidence continued drug stability before proceeding with medicines reuse. Some 
thought that not all types of formulations would be suitable for reuse. 
“Need to see published trials.” (Participant 192). 
“Only reuse quality medications not generics.” (Participant 88). 
“Adhesive on morphine patches not of best quality.” (Participant 82). 
3.2.2. Specially Regulated Products 
This theme acknowledges the regulations of medicines by authorities such as the 
medicines and healthcare products regulatory agency (MHRA) to ensure quality, safety 
and efficacy standards are achieved and maintained before and after the licensing and 
marketing of medicines. This includes giving expiry dates and specifying storage condi-
tions to preserve and maintain shelf life and prevent drug degradation. Although many 
of the participants expressed pro-medicines reuse intentions, some still commented on the 
potential impact of the storage environment on medicines and whether this would affect 
their quality. Concerns were also expressed on the safety and authenticity of drugs, as it 
is difficult to verify how and where medicines have been kept and handled. For example: 
“Conditions under which it may have been stored are unknown e.g., insulin in fridge.” 
(Participant 90). 
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“Many people will be afraid that re-using meds runs a risk of contamination.” (Partic-
ipant 36). 
“Even though the medication would appear to be sealed in its original packaging you 
don’t know how it has been stored, this could have an effect on it if stored in too hot or 
too cold temperatures.” (Participant 66). 
“Proof of stability is a big concern.” (Participant 38). 
3.2.3. Unique to an Individual’s Health 
This theme relates to the purposeful selection and prescribing of medicines to treat 
someone’s health condition. Healthcare professionals will have carefully chosen a specific 
medicine, from a range of treatment options, to suit the individual’s needs. The therapeu-
tic effects and outcomes of a medicine, it follows, will be dependent on the patient’s 
unique set of circumstances, as determined by the health professional. Accordingly, med-
icines should not be shared because their outcomes cannot be guaranteed under a differ-
ent set of circumstances—instead, when no longer needed, medicines ought to be returned 
to the pharmacy for disposal. In this way, medicines are quite unlike ordinary commodi-
ties. The survey was completed by people with chronic health conditions. Many re-
sponded considering their own medicines, such as antidiabetics on which they rely to re-
main well. In addition, some comments conveyed a strong desire to adhere to advice given 
by health professionals, as the experts in their field. This theme highlights the complexity 
of medicines and the supervision that is needed alongside their usage. For example: 
“I am type 1 diabetic and don't feel that reusing medication is for any diabetic.” (Par-
ticipant 203). 
“I would reuse sealed medication only if my Dr said it was safe.” (Participant 5). 
3.2.4. Handling to Meet Legal and Practice Guidelines 
According to this theme, the dispensing of prescription-only medicines (POMs) car-
ried out by trained staff and checks by pharmacists must be accurate and follow protocols, 
such as standard operating procedures (SOPs) to maximize patient safety and care. This 
is because medicines are powerful and valuable and can be susceptible to misuse or cause 
harm if mishandled. This was a commonly occurring theme. Individuals cautioned 
against reusing medicines, highlighting negative repercussions if they are handled casu-
ally. Thus, quality checks by trained health professionals were deemed essential to assess 
the safety and appropriateness of medicines for use, central to patient care. A few partic-
ipants also commented on the possibility of fake medicines entering the supply chain, 
which further necessitated the need for thorough checks. Thus, medicines are not the same 
as other commodities as there is a lot more at stake should they be mismanaged. 
“I worry about fake medication.” (Participant 28). 
“Providing everything has been checked out by professionals and have long use by date.” 
(Participant 96). 
“There would need to be very strict guidelines in place to ensure patient safety.” (Par-
ticipant 130). 
4. Discussion 
This research is important because it unearths how people think about medicines and 
the properties that make them reusable or not. The category of “medicines as common 
commodities” encapsulates commonly held ideas about what makes medicines the same 
as any other commodity and therefore suitable for reuse, and the category of “medicines 
as powerful potions” describes what confers medicines their potency and special status, 
distinct from ordinary commodities thus cautioning against their reuse. These categories 
highlight the contradictory ways in which medicines can be viewed by different, and 
sometimes even the same people, and helps explain how medicines can be deemed both 
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reusable and not reusable. The findings can help policy makers understand what makes 
people (even themselves) receptive to the idea of medicines reuse and importantly, how 
existing medicines reuse practices (e.g., visual inspections) might in fact be more in line 
with the everyday view of medicines as common commodities rather than the “powerful 
potions” view normally advocated by biomedicine. 
A strength of this study is that the primary data came from a survey that captured 
views about medicines reuse from a representative sample of the UK patient population 
[22]. The sample was representative in terms of gender, ethnicity, geographical location 
and education level. As such, the data can be generalised to the wider population, and 
therefore displays some level of external validity. Additionally, as the data came from 
patients with chronic conditions who are more likely to be using medicines regularly, their 
opinions towards reuse would be expected to be more meaningful than if gathered from 
healthy volunteers. A weakness is that the study relied on the analysis of static comments 
written in an online survey where it was not possible to seek further information or justi-
fication to the answers provided. Another limitation of the study is that, although suffi-
cient for a qualitative analysis, only 210 respondents made written comments on the ques-
tionnaire, which represented a fifth of the overall number of participants. 
The majority of the comments from the survey belonged in the category of medicines 
as common commodities, with only a quarter reflecting medicines as powerful potions. 
Commodities are standardized goods or services enabling an exchange or sale between 
the manufacturers/providers and consumers; of economic value, commodities are primar-
ily produced to meet market demand and satisfy individuals’ needs [24]. Medical anthro-
pologists’ examination of medicines as commodities positions these with social, cultural 
and economic aspects far beyond their material (chemical) properties [25]. As such, med-
icines are commodities for exchange with social lives, and different life stages and roles 
as they move from one setting to another, i.e., from manufacturers to marketing, prescrip-
tion by healthcare professionals, and dispensing by pharmacies for patients’ use [26]. This 
notion of commodification contrasts with a biomedical understanding, where, in line with 
the category of powerful potions, medicines are classified according to potency, are re-
stricted and regulated in their use and given specific directions for storage and admin-
istration, marking them as highly distinct from everyday commodities. 
Dichotomous representations of medicines are not new. For example, in previous 
work, medication has been described as “marvellous medicines” versus “dangerous 
drugs” [27]. Similarly, when antipsychotics are prescribed in dementia, they are either 
“the lesser of two evils” or “medicines not smarties” [28]. In this study, the dichotomiza-
tion explains what on the one hand permits the reuse of medicines but on the other inhibits 
it. The participants’ notion of medicines as ordinary commodities was most commonly 
captured by the theme of social and economic benefits, followed by the themes of the so-
cial life of medicines and physical appearance. Thinking about medicines in terms of their 
economic value is not new and examining the literature, studies promoting medicines re-
use, including our own [20], do tend to cite cost savings as a viable reason to explore the 
practice [29,30]. However, the economic argument is only part of the equation. 
In their 1989 paper, Van der Geest and Whyte [31] argued that the “thinginess” of 
medicines makes them democratic; medicines are thought to contain the power of healing 
in themselves, thus anyone who “gains access to them can apply their power”. This is 
what makes medicines transactable and subject to commoditization. However, Van der 
Geest and Whyte [31] also argued medicines are “enclaved commodities” because their 
biochemical properties necessitate in-depth knowledge about disease and people’s func-
tioning when they are handled; health professionals thus attempt to limit access to medi-
cines to prevent waste, misuse or harm. This is despite countless strategies of diversion 
by people that include selling, stealing, smuggling, hoarding, forging, exchanging and 
using medicines as gifts [31]. Seen in this light, it could be argued that the category of 
medicines as “powerful potions” is in line with health professionals’ view of them as “en-
claved commodities”, which explains why returned medicines are normally kept safe by 
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pharmacists and sent away for disposal (so that further access to them is prevented). In-
deed, the need to meet legal and practice guidelines, and being specially regulated prod-
ucts, were the main themes that distinguished medicines as powerful potions that needed 
special caution if to be reused. On the other hand, it could be argued that seeing medicines 
as “common commodities”, in line with the notion of the democratization of medicines 
explains why so many patients returning their unwanted medicines to pharmacies voice 
a request for these to be reused. It also explains the illicit medicines reuse practices iden-
tified in the introduction to this paper. 
Seeing medicines as both similar and different to other commodities at the same time 
is perhaps the key to why even government decision makers are willing to accept the no-
tion of medicines reuse under certain circumstances even when this practice is normally 
unthinkable to them. For example, medicines reuse was permitted when the availability 
of medicines was threatened during the recent pandemic [17]—presumably because it was 
better to have a product available, albeit one that might be less potent, to meet market 
demand, than to have none at all. However, the dichotomization unearthed in this study 
does not actually justify this approach. After all, as argued earlier, the visual inspection of 
medicines cannot actually guarantee their safety. This is because it is possible that the 
active ingredient of the medication degrades, or the formulation breaks down so that ul-
timately less of the medicine is available to treat the disease, even if the packaging passes 
visual checks. Due to the plausible weaknesses in mere visual checks, we propose a more 
robust mechanism using the novel ReMINDS (www.reading.ac.uk/ReMINDS; accessed 
on 16 April 2021) ecosystem as a solution for reusing returned prescribed medicines. This 
system relies on active sensing technologies integrated with the Internet of Things plat-
form to validate the quality and safety of the medicines while interconnecting the relevant 
stakeholders [32,33]. Such a system would acknowledge medicines as both “powerful po-
tions” but also as transactable things, subject to commoditization. In this way, it would be 
possible to recognize the social and economic benefit of medicines reuse without relin-
quishing the biomedical principles that ensure the potency and special status of medi-
cines. Future studies will aim to explore the use of such technologies in order to make 
medicines reuse a safe and effective process. 
5. Conclusions 
This study unearthed people’s interpretations of the properties of medicines that 
make them reusable or not reusable. Two categories of “medicines as common commod-
ities” and “medicines as powerful potions” were generated. Although these categories 
appear to contradict each other, they conceivably also provide the key as to why people 
want medicines reuse to take place on a wider scale and why even governments allow the 
practice in emergencies. Arguably, even health professionals and policy makers who ad-
vocate medicines reuse based on cursory visual checks are won over by the argument of 
medicines as common commodities in contrast with their biomedical training which nor-
mally safely posits medicines within the realm of “powerful potions”. However, rather 
than compromising on quality and safety in order to meet market demands, developing 
and using active sensing technologies could be the key to ensuring a plausible medicines 
reuse practice in the future, allowing the value and social life of medicines to be fully 
realized while protecting the public from potential harm. 
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